HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

SARS-CoV-2 BA.2 (Omicron) variant infection in pediatric liver transplanted recipients and cohabitants during 2022 Shanghai outbreak: a prospective cohort.

AbstractBACKGROUND:
The Omicron variant BA.2 was the dominant variant in the COVID-19 outbreak in Shanghai since March 2022. We aim to investigate the characteristics of SARS-CoV-2 Omicron variant infection in pediatric liver-transplanted recipients.
METHODS:
We conducted a single-center, prospective, observational, single-arm study. We enrolled pediatric liver-transplanted patients infected with the Omicron variant BA.2 from March 19th to October 1st, 2022 and analyzed their demographic, clinical, laboratory, and outcome data. The management of COVID-19 was conducted according to the 9th trial edition of the Chinese guideline. The immunosuppressive therapy was tailored considering the patients' infection developments and liver functions.
RESULTS:
Five children were included. The primary diseases included Niemann-Pick disease, propionic acidemia, decompensated cirrhosis, biliary atresia, and Crigler-Najjar syndrome type I. All of the patients were onset with fever before or when getting RNA-positive results at the age of 3 (Range: 1-13) years. The infection duration was 29 (Range: 18-40) days. Three and two children were diagnosed with mild and moderate COVID-19 respectively. Two patients were tested RNA-positive within 14 days after having been tested negative. The immunosuppressants were paused or extenuated in four patients. Eight of all nine cohabitants were injected with at least two doses of inactivated SARS-CoV-2 vaccine. The disease courses were significantly longer than the patients (P < 0.05).
CONCLUSIONS:
Post-transplant immunosuppression slows down the virus clearance and increases the risk of relapse but does not affect symptom duration or infection severity in pediatric patients. Patients can usually gain a favorable outcome and prognosis by extenuating immunosuppressants.
AuthorsXin-Ye Zhu, Ye-Feng Lu, Feng Xue, Yi Luo, Ming-Xuan Feng, Bi-Jun Qiu, Tao Zhou, Jian-Jun Zhu, Jian-Jun Zhang, Ping Wan, Qiang Xia
JournalVirology journal (Virol J) Vol. 20 Issue 1 Pg. 28 (02 11 2023) ISSN: 1743-422X [Electronic] England
PMID36774503 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2023. The Author(s).
Chemical References
  • COVID-19 Vaccines
  • Immunosuppressive Agents
Topics
  • Humans
  • Child
  • Infant
  • Child, Preschool
  • Adolescent
  • COVID-19 (epidemiology)
  • COVID-19 Vaccines
  • Propionic Acidemia
  • Prospective Studies
  • SARS-CoV-2 (genetics)
  • China (epidemiology)
  • Disease Outbreaks
  • Immunosuppressive Agents (adverse effects)
  • Liver

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: